Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03519477
Other study ID # SAN_UPMC_CV_001
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date September 2018
Est. completion date January 21, 2019

Study information

Verified date August 2018
Source Precera Bioscience, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the clinical utility of comprehensive medication monitoring using the Patient Medication Profile to improve heart failure patient medication therapy and associated outcomes relative to usual care in a hospital setting.


Description:

Congestive heart failure has an exceptionally high rate of hospital admission and is responsible for more re-admissions (23.5% at 30 days) in the United States than the 2nd and 3rd leading causes combined. Inadequate medication reconciliation both on admission and discharge from the hospital is a significant cause of medical error. In one study of cardiovascular patients, 44% believed they were taking a medication they were not, and 96% were unable to recall at least one medication they were taking. In the same study patients omitted on average 6.8 medications from their medication list. Medication optimization through improved adherence and reconciled medical records has been postulated to significantly improve admission and 30-day hospital readmission rates.

Sano has developed a blood-based comprehensive medication monitoring tool that identifies and quantitates 235 prescription drugs and drug metabolites. It does not detect illicit drugs. This tool, which produces an output report designated the 'Patient Medication Profile', is designed to be used with clinical decision support to improve medication adherence, reduce medication errors, and optimize medication therapy. For heart failure patients, the investigators hypothesize that deploying the Patient Medication Profile with clinical decision support at key points of treatment intervention will A) improve medication adherence, B) identify and reconcile significant discrepancies in the medication list, C) result in reduced hospital admissions, and D) result in better overall patient outcomes. These outcome expectations are relative to usual care for heart failure patients.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date January 21, 2019
Est. primary completion date January 21, 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patients must have a regularly scheduled visit to a University of Pittsburgh Medical Center (UPMC) cardiology clinic in Oakland

- Patients must have Heart Failure with Reduced Ejection Fraction (=40%)

- Patients have admitted to UPMC hospital facility between one and five times in past 12 months

- Patients must be able to provide informed consent for present study

- Patient age > 18 years

Exclusion Criteria:

- Enrolled in Hospice

- Patient on home inotrope (Dobutamine or milrinone)

- World Health Organization (WHO) Group 1 or Group 5 pulmonary hypertension

- Patient with current ventricular assist device (VAD)

- Not able to communicate in English

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Sano Patient Medication Profile
The Sano Patient Medication Profile (PMP) is a graphical report comparing prescribed medications to liquid (chromatography/tandem mass-spectrometry) LC/MS/MS-detected drugs from patient blood samples

Locations

Country Name City State
United States UPMC Heart and Vascular Institute Pittsburgh Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Precera Bioscience, Inc. University of Pittsburgh

Country where clinical trial is conducted

United States, 

References & Publications (2)

Cumbler E, Wald H, Kutner J. Lack of patient knowledge regarding hospital medications. J Hosp Med. 2010 Feb;5(2):83-6. doi: 10.1002/jhm.566. — View Citation

Gupta P, Patel P, Štrauch B, Lai FY, Akbarov A, Marešová V, White CMJ, Petrák O, Gulsin GS, Patel V, Rosa J, Cole R, Zelinka T, Holaj R, Kinnell A, Smith PR, Thompson JR, Squire I, Widimský J Jr, Samani NJ, Williams B, Tomaszewski M. Risk Factors for Nonadherence to Antihypertensive Treatment. Hypertension. 2017 Jun;69(6):1113-1120. doi: 10.1161/HYPERTENSIONAHA.116.08729. Epub 2017 May 1. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in adherence to prescribed cardiology medications For each patient, the proportion of prescribed medications that are detected using the baseline and final PMP will be calculated; change in adherence will be defined as proportion using final PMP, minus proportion using baseline PMP. Compare adherence difference in intervention vs. control groups. 30 days
Secondary Number of hospital admissions per patient within 90 days of enrollment in intervention vs. control group 90 days
Secondary Baseline adherence to prescribed cardiology medications as a predictor of hospital admission for heart failure within 90 days Baseline adherence to prescribed cardiology medications as a predictor of hospital admission for heart failure within 90 days. This endpoint will use baseline adherence and the Patient Medication Profile will not have been discussed with the care team in the intervention group, therefore both intervention and control groups will be pooled 90 days
Secondary Drug Related Problem identification and resolution Documented drug related problems identified by medication reconciliation will be compared between the intervention and control groups. The number of changes in medications to resolve drug related problems, such as medication additions, terminations, dosage or frequency changes will be compared between the intervention and control groups. 30 days
See also
  Status Clinical Trial Phase
Completed NCT03727646 - Nicotinamide Riboside in LVAD Recipients Early Phase 1
Recruiting NCT05596760 - Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers N/A
Recruiting NCT05227872 - PVF in Decongestion of Heart Failure
Recruiting NCT05543720 - Evaluation of Nurse-led Integrated Care of Complex Patients Facilitated By Telemonitoring: The SMaRT Study N/A
Completed NCT04572425 - Virtual Reality for Pain Management in Advanced Heart Failure N/A
Recruiting NCT03202329 - Evaluation of Post-operative, Nurse-based Heart Failure Care in Non-cardiac Surgery N/A
Recruiting NCT03830957 - Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker N/A
Recruiting NCT02672618 - Clinical Research to Explore Manifestations of Heart Failure Using Infrared Thermal Imaging Technology N/A
Recruiting NCT04179643 - NAN-101 in Patients With Class III Heart Failure Phase 1
Completed NCT04129658 - Heart Failure in Southern Sweden
Not yet recruiting NCT05591443 - Artificial Intelligence and Smart Wearable Technologies for Early Detection of Acute Heart Failure
Completed NCT03387813 - Hemodynamic-GUIDEd Management of Heart Failure N/A
Completed NCT04628325 - Effects of Furosemide Plus Small HSS in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) Phase 3
Completed NCT03187470 - Left Ventricular Dyssynchrony in Multipole Pacing N/A
Completed NCT03385837 - Activity Level and Barriers to Participate of Cardiac Rehabilitation in Advanced Heart Failure Patients
Completed NCT04281849 - Balance, Aerobic Capacity, Mobility and Strength in Patients Hospitalized for Heart Failure (BAMS-HF) Program N/A
Not yet recruiting NCT04403659 - Telemonitoring of Patients Admitted in Hospital at Home With Acute Decompensated Heart Failure - Pilot Study N/A
Terminated NCT04142788 - RELieving Increasing oEdema Due to Heart Failure Phase 4
Active, not recruiting NCT04283994 - Project to Improve Communication About Serious Illness--Hospital Study: Comparative Effectiveness Trial (Trial 2) N/A
Completed NCT03722069 - Dietary Sodium Intake in Acute Heart Failure N/A